$3.90
-0.11-2.81%
最終更新: Oct 13, 10:44 AM
$4.01
N/A
Benzinga
Benzinga
Benzinga
火曜日, 10 13
Benzinga
© 2026 Benzinga | All Rights Reserved
Recursion Pharmaceuticals (RXRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.24 | $-0.27 | $-0.30 | $-0.38 |
| Actual | $-0.25 | $-0.22 | $-0.21 | $-0.36 |
| Surprise | -4.17% | +18.5% | +30.0% | +5.26% |
| Revenue | ||||
| Estimate | $12.9M | $15.9M | $24.9M | $18.6M |
| Actual | $7.7M | $6.5M | $35.5M | $5.2M |
| Surprise | -40.7% | -59.2% | +42.5% | -72.2% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.23 | $-0.23 | $-0.23 | $-0.24 |
| Revenue | ||||
| Consensus | $12.1M | $14.1M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.25 | $-0.24 | -4.17 % |
| Q1 | May 6, 2026 | $-0.22 | $-0.27 | 18.5 % |
| Q4 | Feb 25, 2026 | $-0.21 | $-0.30 | 30.0 % |
| Q3 | Nov 5, 2025 | $-0.36 | $-0.38 | 5.26 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $7.67M | $12.93M | -40.7 % |
| Q1 | May 6, 2026 | $6.47M | $15.86M | -59.2 % |
| Q4 | Feb 25, 2026 | $35.54M | $24.93M | 42.5 % |
| Q3 | Nov 5, 2025 | $5.18M | $18.60M | -72.2 % |